Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by China Medical University Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01240369
First received: November 11, 2010
Last updated: November 12, 2010
Last verified: November 2010

November 11, 2010
November 12, 2010
October 2010
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01240369 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma
Not Provided

Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer. Clinically, over 80% of patients with cancer were at late stage when they were diagnosed. Therefore, it is important for us to find the biomarker that serve as the early prediction of cancer.

The investigators have published that VEGFC over-expressed in non-small cell lung cancer. VEGFC plays a critical role in regulating motility of tumor cells, promotes proliferation of lymphatic endothelial cells and enhances migration and invasion. Investigator found that VEGFC over-expressed in the serum of esophageal cancer patients. Therefore, it is worthwhile to investigate the correlation between VEGFC, clinical lung cancer and esophageal cancer.

MicroRNAs (miRNAs) are conserved, endogenous, small, and noncoding RNA molecules of 21~23 nucleotides that function as post-transcriptional gene regulators. Recent studies indicated that certain microRNAs reduced in cancer patients. Therefore it is important to investigate whether specific microRNA changed in certain kinds of cancer patients.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

ESCC and NSCLC patients

  • VEGFC Protein in Serum
  • VEGFC Protein in Non Small Cell Lung Cancer
  • VEGFC Protein in ESCC
  • CTTN Protein in ESCC
  • miR326 in ESCC and Non Small Cell Lung Cancer
Not Provided
  • VEGF-C low
  • VEGF-C high
  • miR-326 low
  • miR-326 high
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
250
Not Provided
Not Provided

Inclusion Criteria:

  • tumor size > 0.5 cm3

Exclusion Criteria:

  • tumor size < 0.5 cm3
Both
50 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01240369
DMR99-IRB-206
Yes
Jen-Liang Su, China Medical University Hospital
China Medical University Hospital
Not Provided
Not Provided
China Medical University Hospital
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP